Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease

Annals of Medicine

Volumn 44, Issue 3, 2012, Pages 262-270

  Holzmann, Martin J ^a,b   Jungner, Ingmar ^d,e   Walldius, Göran ^b,d   Ivert, Torbjörn ^a   Nordqvist, Tobias ^c   Östergren, Jan ^a,b   Hammar, Niklas ^b,f  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Stockholm Centre of Public Health   (Sweden)

^d Swedish Board of Health and Welfare   (Sweden)

^e CALAB Research   (Sweden)

^f ASTRAZENECA R AND D   (Sweden)

Author keywords

Apolipoproteins; Kidney; Myocardial infarction; Prognosis; Risk factors

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HEART INFARCTION; HUMAN; LABORATORY TEST; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; STRATIFIED SAMPLE;

ADULT; APOLIPOPROTEINS; CHOLESTEROL; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; ROC CURVE;

EID: 84859317128     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2010.532153     Document Type: Article

References (28)

1. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154-69. (Pubitemid 37337595)
2. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffi th JL, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41:47-55. (Pubitemid 36044403)
3. Brugts JJ, Knetsch AM, Mattace-Raso FU, Hofman A, Witteman JC. Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study. Arch Intern Med. 2005;165:2659-65. (Pubitemid 41785065)
4. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insuffi ciency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13:745-53. (Pubitemid 34183941)
5. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med. 2004;140:9-17.
6. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehmann-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005;293:1737-45.
7. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol. 2005;16:529-38. (Pubitemid 41725151)
8. Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med. 2006;166:1884-91. (Pubitemid 44455172)
9. Vaziri ND, Moradi H. Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int. 2006;10:1-7. (Pubitemid 43263285)
10. Samuelsson O, Attman PO, Knight-Gibson C, Kron B, Larsson R, Mulec H, et al. Lipoprotein abnormalities without hyperlipidaemia in moderate renal insuffi ciency. Nephrol Dial Transplant. 1994;9:1580-5. (Pubitemid 24344773)
11. de Boer IH, Astor BC, Kramer H, Palmas W, Seliger SL, Shlipak MG, et al. Lipoprotein abnormalities associated with mild impairment of kidney function in the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol. 2008;3:125-32.
12. Elovson J, Chatterton JE, Bell GT, Schumaker VN, Reuben MA, Puppione DL, et al. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res. 1988;29:1461-73. (Pubitemid 19013040)
13. Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med. 2004;42:1355-63. (Pubitemid 40057822)
14. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a fi ve-year follow-up of men in the Quebec cardiovascular study. Circulation. 1996; 94:273-8. (Pubitemid 26266109)
15. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112:3375-83. (Pubitemid 43739551)
16. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026-33. (Pubitemid 34084825)
17. Benn M, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol. 2007;27:661-70.
18. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005; 294:326-33. (Pubitemid 41043776)
19. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104:1108-13. (Pubitemid 32830392)
20. van der Steeg WA, Boekholdt SM, Stein EA, El-Harchaoui K, Stroes ES, Sandhu MS, et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med. 2007;146:640-8. (Pubitemid 351650519)
21. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007;298:776-85. (Pubitemid 47263160)
22. Jungner I, Marcovina SM, Walldius G, Holme I, Kolar W, Steiner E. Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials. Clin Chem. 1998;44:1641-9. (Pubitemid 28381205)
23. Jungner I, Walldius G, Holme I, Kolar W, Steiner E. Apolipoprotein B and A-I in relation to serum cholesterol and triglycerides in 43,000 Swedish males and females. Int J Clin Lab Res. 1992;21:247-55.
24. Talmud PJ, Hawe E, Miller GJ, Humphries SE. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol. 2002;22:1918-23. (Pubitemid 35315782)
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
26. Coresh J, Selvin E, Stevens LA, Manzi, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038-47. (Pubitemid 350074801)
27. Levey A, Greene T, Kusek JW, Beck GJ. A simplifi ed equation to predict glomerular fi ltration rate from serum creatinine. J Am Soc Nephrol. 2000;(155A).
28. Rothman KJ, Greenland, S. Modern epidemiology. Vol 2. 2nd ed. Philadelphia: Lippincott-Raven; 1998.